TP53 and neoplasm: The anti-tumor effect of pharmacological MDM2 inhibition was tested using a selective small-molecule inhibitor (RG7388) which inhibited cell proliferation through apoptosis induction and cell cycle blockade, and inhibited wt p53-RTK NSCLC tumor growth in xenograft models.